Phase I/IIa dose finding study of triplet regimen of relatlimab (RELA), ipilimumab (IPI), and nivolumab (NIVO) in first-line therapy of metastatic melanoma (TRINITY).

Authors: Elizabeth M. Burton, Tara Marie Davidson, Krysta McVay, Denai R. Milton, Rodabe Navroze Amaria, Isabella Claudia Glitza, Jennifer Leigh McQuade, Theresa H. Nguyen, Alexandra Ikeguchi, Adi Diab, Weiyi Peng, Michael A. Davies, Hussein A. Tawbi

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9593

Source: Full article

---

Abstract

TPS9593